{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:05:28Z","timestamp":1790373928467,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009362","name":"South London and Maudsley NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jsat.2019.06.007","type":"journal-article","created":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T01:11:18Z","timestamp":1560042678000},"page":"64-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder"],"prefix":"10.1016","volume":"104","author":[{"given":"Charlotte N.E.","family":"Tompkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Neale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Strang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jsat.2019.06.007_bb0005","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/jvh.12415","article-title":"Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: The ETHOS study","volume":"22","author":"Alavi","year":"2015","journal-title":"Journal of Viral Hepatitis"},{"issue":"2","key":"10.1016\/j.jsat.2019.06.007_bb0010","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s12325-016-0472-9","article-title":"Pharmacokinetic evaluation of once-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: An open-label phase 1 study","volume":"34","author":"Albayaty","year":"2017","journal-title":"Advances in Therapy"},{"issue":"3","key":"10.1016\/j.jsat.2019.06.007_bb0015","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/02791072.2010.10400696","article-title":"Heroin-dependent inmates' experiences with buprenorphine or methadone maintenance","volume":"42","author":"Awgu","year":"2010","journal-title":"Journal of Psychoactive Drugs"},{"issue":"3","key":"10.1016\/j.jsat.2019.06.007_bb0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/2045125316681984","article-title":"Probuphine\u00ae (buprenorphine implant): A promising candidate in opioid dependence","volume":"7","author":"Barnwal","year":"2017","journal-title":"Therapeutic Advances in Psychopharmacology"},{"key":"10.1016\/j.jsat.2019.06.007_bb0025","series-title":"Medications in recovery: Re-orientating drug dependence treatment","article-title":"Appendix C \u2013 Opioid substitution treatment and its effectiveness: Review of the evidence","author":"Bell","year":"2012"},{"key":"10.1016\/j.jsat.2019.06.007_bb0030","series-title":"Goodman and Gilman's the pharmacological basis of therapeutics","year":"2017"},{"key":"10.1016\/j.jsat.2019.06.007_bb0035","author":"Camurus AB"},{"key":"10.1016\/j.jsat.2019.06.007_bb0040","author":"Camurus AB"},{"key":"10.1016\/j.jsat.2019.06.007_bb0045","author":"Camurus AB"},{"issue":"6","key":"10.1016\/j.jsat.2019.06.007_bb0050","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.drugpo.2013.04.004","article-title":"Substance, structure and stigma: Parents accounting for opioid substitution therapy during the antenatal and postnatal periods","volume":"24","author":"Chandler","year":"2013","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.jsat.2019.06.007_bb0055","series-title":"Drug misuse and dependence: UK guidelines on clinical management","author":"Clinical Guidelines on Drug Misuse and Dependence Update 2017","year":"2017"},{"issue":"3","key":"10.1016\/j.jsat.2019.06.007_bb0060","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2016.8897","article-title":"Improving outcomes for persons with opioid use disorders buprenorphine implants to improve adherence and access to care","volume":"316","author":"Compton","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jsat.2019.06.007_bb0065","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.drugpo.2013.07.004","article-title":"Shouting through bullet-proof glass: Some reflections on pharmacotherapy provision in one Australian clinic","volume":"24","author":"Crawford","year":"2013","journal-title":"International Journal of Drug Policy"},{"issue":"3","key":"10.1016\/j.jsat.2019.06.007_bb0070","first-page":"384","article-title":"Do patients' expectations influence their use of medications? Qualitative study","volume":"54","author":"Dolovich","year":"2008","journal-title":"Canadian Family Physician"},{"key":"10.1016\/j.jsat.2019.06.007_bb0075","series-title":"Summary of opinion: Sixmo buprenorphine","author":"European Medicines Agency","year":"2019"},{"key":"10.1016\/j.jsat.2019.06.007_bb0080","series-title":"European drug report 2017: Trends and development","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2017"},{"issue":"5","key":"10.1016\/j.jsat.2019.06.007_bb0085","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/ADM.0000000000000057","article-title":"Factors affecting noncompliance with buprenorphine maintenance treatment","volume":"8","author":"Fareed","year":"2014","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2019.06.007_bb0090","series-title":"Substance and substitution: Methadone subjects in liberal societies","author":"Fraser","year":"2008"},{"key":"10.1016\/j.jsat.2019.06.007_bb0095","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2147\/PPA.S180641","article-title":"Current and future options for opioid use disorder: A survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine","volume":"12","author":"Gilman","year":"2018","journal-title":"Patient Preference and Adherence"},{"issue":"93(1\u20132)","key":"10.1016\/j.jsat.2019.06.007_bb0100","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.drugalcdep.2007.09.008","article-title":"Barriers associated with the treatment of hepatitis C virus infection among illicit drug users","volume":"11","author":"Grebley","year":"2008","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2019.06.007_bb0105","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jsat.2017.04.008","article-title":"Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder","volume":"78","author":"Haasen","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.06.007_bb0110","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.jsat.2019.06.007_bb0115","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/1049732311432718","article-title":"Methadone as social control: Institutionalized stigma and the prospect of recovery","volume":"22","author":"Harris","year":"2012","journal-title":"Qualitative Health Research"},{"issue":"1","key":"10.1016\/j.jsat.2019.06.007_bb0120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00002508-200301000-00004","article-title":"Factors associated with willingness to try different pain treatments for pain after a spinal cord injury","volume":"19","author":"Haythornthwaite","year":"2003","journal-title":"The Clinical Journal of Pain"},{"key":"10.1016\/j.jsat.2019.06.007_bb0125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4103\/0253-7176.112194","article-title":"Long-acting preparations in substance abuse management: A review and update","volume":"35","author":"Hegde","year":"2013","journal-title":"Indian Journal of Psychological Medicine"},{"issue":"3","key":"10.1016\/j.jsat.2019.06.007_bb0130","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3109\/14659891.2014.894589","article-title":"A comparison of methadone and buprenorphine\u2013naloxone as opioid substitution therapy: The patient perspective in NHS Lanarkshire","volume":"20","author":"Hill","year":"2015","journal-title":"Journal of Substance Use"},{"key":"10.1016\/j.jsat.2019.06.007_bb0135","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.2147\/DDDT.S109331","article-title":"New developments in managing opioid addiction: Impact of a subdermal buprenorphine implant","volume":"11","author":"Itzoe","year":"2017","journal-title":"Drug Design, Development and Therapy"},{"issue":"3","key":"10.1016\/j.jsat.2019.06.007_bb0140","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/00952990.2011.643983","article-title":"A comparison of attitudes toward opioid agonist treatment among short-term buprenorphine patients","volume":"38","author":"Kelly","year":"2012","journal-title":"American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.jsat.2019.06.007_bb0145","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jsat.2018.08.011","article-title":"Buprenorphine treatment formulations: Preferences among persons in opioid withdrawal management","volume":"94","author":"Kenney","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.06.007_bb0150","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1001\/jama.2010.1427","article-title":"Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial","volume":"304","author":"Ling","year":"2010","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.jsat.2019.06.007_bb0155","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: A randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Internal Medicine"},{"issue":"2","key":"10.1016\/j.jsat.2019.06.007_bb0160","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/JAN.0000000000000223","article-title":"Sublocade the once-monthly buprenorphine injectable","volume":"29","author":"Lorman","year":"2018","journal-title":"Journal of Addictions Nursing"},{"key":"10.1016\/j.jsat.2019.06.007_bb0165","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/1472-6963-14-469","article-title":"Factors affecting the uptake of new medicines: A systematic literature review","volume":"14","author":"Lubl\u00f3y","year":"2014","journal-title":"BMC Health Services Research"},{"issue":"11","key":"10.1016\/j.jsat.2019.06.007_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207226","article-title":"Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?","volume":"13","author":"Madden","year":"2018","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jsat.2019.06.007_bb0175","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/j.1360-0443.2011.03424.x","article-title":"The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine\/naloxone tablets in opioid abusers","volume":"106","author":"Middleton","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.06.007_bb0180","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/JCP.0000000000000434","article-title":"Sustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder","volume":"36","author":"Nasser","year":"2016","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.jsat.2019.06.007_bb0185","author":"National Institute on Drug Abuse (NIDA)"},{"key":"10.1016\/j.jsat.2019.06.007_bb0190","author":"National Institute on Drug Abuse (NIDA)"},{"issue":"6","key":"10.1016\/j.jsat.2019.06.007_bb0195","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.drugpo.2013.08.003","article-title":"Opioid pharmacotherapy: Treatment, regimes, constructions and control","volume":"24","author":"Neale","year":"2013","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.jsat.2019.06.007_bb0200","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/add.13314","article-title":"Iterative categorisation (IC): A systematic technique for analysing qualitative data","volume":"111","author":"Neale","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.06.007_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2018.03.057","article-title":"Implants and depot injections for treating opioid dependence: Qualitative study of people who use or have used heroin","volume":"189","author":"Neale","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"26(6)","key":"10.1016\/j.jsat.2019.06.007_bb0210","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1037\/pha0000217","article-title":"Patient views of opioid pharmacotherapy bio-delivery systems: Qualitative study to assist treatment decision making","volume":"23","author":"Neale","year":"2018","journal-title":"Experimental and Clinical Psychopharmacology"},{"issue":"6","key":"10.1016\/j.jsat.2019.06.007_bb0215","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.drugpo.2013.09.009","article-title":"The politics of providing opioid pharmacotherapy","volume":"24","author":"Radcliffe","year":"2013","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.jsat.2019.06.007_bb0220","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.2147\/DDDT.S72543","article-title":"Advances in the delivery of buprenorphine for opioid dependence","volume":"11","author":"Rosenthal","year":"2017","journal-title":"Drug Design, Development & Therapy"},{"key":"10.1016\/j.jsat.2019.06.007_bb0225","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/add.12315","article-title":"Buprenorphine implants for treatment of opioid dependence: Randomized comparison to placebo and sublingual buprenorphine\/naloxone","volume":"108","author":"Rosenthal","year":"2013","journal-title":"Addiction"},{"issue":"5051","key":"10.1016\/j.jsat.2019.06.007_bb0230","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in drug and opioid-involved overdose deaths: United States, 2010\u20132015","volume":"65","author":"Rudd","year":"2016","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"5","key":"10.1016\/j.jsat.2019.06.007_bb0235","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1080\/10550490802268835","article-title":"Attitudes toward buprenorphine and methadone among opioid-dependent individuals","volume":"17","author":"Schwartz","year":"2008","journal-title":"American Journal on Addictions"},{"key":"10.1016\/j.jsat.2019.06.007_bb0240","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/add.13539","article-title":"Food and drug administration approval of sustained release buprenorphine for treatment of opioid dependence: Realizing its potential","volume":"112","author":"Sigmon","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.06.007_bb0245","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"British Medical Journal"},{"key":"10.1016\/j.jsat.2019.06.007_bb0250","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1517\/14656560903037168","article-title":"Opioid dependence treatment: Options in pharmacotherapy","volume":"10","author":"Stotts","year":"2009","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.jsat.2019.06.007_bb0255","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.drugpo.2013.05.005","article-title":"What is low threshold methadone maintenance treatment?","volume":"24","author":"Strike","year":"2013","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.jsat.2019.06.007_bb0260","author":"The American Society of Addiction Medicine"},{"issue":"6","key":"10.1016\/j.jsat.2019.06.007_bb0265","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.drugpo.2013.04.010","article-title":"Examining structural violence in opioid pharmacotherapy treatment in Australia: Sweating the \u2018small stuff\u2019 in a liberal paradise","volume":"24","author":"Treloar","year":"2013","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.jsat.2019.06.007_bb0270","series-title":"World drug report 2018","author":"United Nations","year":"2018"},{"issue":"1","key":"10.1016\/j.jsat.2019.06.007_bb0275","first-page":"24","article-title":"Implant for opioid dependence","volume":"316","author":"Voelker","year":"2016","journal-title":"Journal of the American Medical Association"},{"issue":"9","key":"10.1016\/j.jsat.2019.06.007_bb0280","first-page":"894","article-title":"Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: A randomized clinical trial","volume":"74","author":"Walsh","year":"2017","journal-title":"Journal of the American Medical Association Psychiatry"},{"issue":"Suppl. 2","key":"10.1016\/j.jsat.2019.06.007_bb0285","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0376-8716(03)00056-5","article-title":"The clinical pharmacology of buprenorphine: Extrapolating from the laboratory to the clinic","volume":"70","author":"Walsh","year":"2003","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.jsat.2019.06.007_bb0290","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/14659890701289463","article-title":"Patients' views of treatment: Methadone vs. buprenorphine","volume":"12","author":"White","year":"2007","journal-title":"Journal of Substance Use"},{"issue":"160","key":"10.1016\/j.jsat.2019.06.007_bb0295","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.12.031","article-title":"Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis","volume":"1","author":"Yarborough","year":"2016","journal-title":"Drug and Alcohol Dependence"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547219301023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547219301023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:50:04Z","timestamp":1760039404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547219301023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":59,"alternative-id":["S0740547219301023"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2019.06.007","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2019.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}